Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
PHASE2
RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritu...
Status
Completed
Location
Comprehensive Cancer Center at University of Alabama at Birmingham
S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone
N/A
RATIONALE: Studying samples of blood and tissue from patients with cancer i...
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
PHASE2
In the present trial the chemotherapy- light treatment concept R-Pola-Glo w...